Skip to main content
. 2019 Oct 22;79(10):1043–1060. doi: 10.1055/a-0882-4116
Consensus-based Recommendation 3.E17
Expert consensus Strength of consensus +++
Reference: 60
There are currently no data about the oncological safety of hormone replacement therapy after previous primary treatment of a low-grade ESS. Because the tumor biology of low-grade ESS is highly estrogen-dependent, patients should be dissuaded from starting hormone replacement therapy.